LMR Partners’s Ionis Pharmaceuticals IONS Stock Holding History

LMR Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.44M	Buy	30,800 +15,800	+105%	+$1.19M	0.01%	843
2026 Q1	$1.13M	Hold	15,000	–	–	﹤0.01%	959
2025 Q4	$1.19M	Sell	15,000 -22,600	-60%	-$1.7M	﹤0.01%	944
2025 Q3	$2.46M	Buy	+37,600	New	+$1.84M	0.01%	674
2020 Q1	–	Sell	-28,809	Closed	-$1.74M	–	341
2019 Q4	$1.74M	Buy	28,809 +24,781	+615%	+$1.48M	﹤0.01%	145
2019 Q3	$241K	Buy	+4,028	New	+$263K	0.01%	335
2019 Q2	–	Sell	-51,950	Closed	-$4.22M	–	506
2019 Q1	$4.22M	Buy	+51,950	New	+$3.35M	0.22%	69
2016 Q4	–	Sell	-144,790	Closed	-$5.3M	–	364
2016 Q3	$5.3M	Buy	+144,790	New	+$4.53M	0.5%	50

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

LMR Partners's IONS Position: Q2 2026 in Review

LMR Partners increased its Ionis Pharmaceuticals (IONS) stake by 105% in Q2 2026, buying an estimated $1.19M and bringing the position to 30,800 shares worth $2.44M. The position accounts for 0.01% of the portfolio, ranked #843.

LMR Partners first reported a position in IONS in Q3 2016 and has held it in 8 quarters since. The position peaked at $5.3M in Q3 2016. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

LMR Partners held 30,800 shares of Ionis Pharmaceuticals worth $2.44M as of Q2 2026.
LMR Partners bought 15,800 Ionis Pharmaceuticals shares in Q2 2026, an estimated $1.19M.
Ionis Pharmaceuticals made up 0.01% of LMR Partners's portfolio in Q2 2026, its #843 holding.
LMR Partners first reported a position in Ionis Pharmaceuticals in Q3 2016 and has held it in 8 quarters since.
LMR Partners's Ionis Pharmaceuticals position peaked at $5.3M in Q3 2016.
514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.